Mostrar el registro sencillo del ítem

Fractalcina/CX3CL1 y su rol en la fisiopatología en esclerosis sistémica

dc.contributor.advisorCruz Vaquero, Claudia Andrea
dc.contributor.advisorRamírez Santana, Carolina
dc.contributor.authorCordoba Mora, Rodrigo Hernán
dc.date.accessioned2024-09-20T13:53:25Z
dc.date.available2024-09-20T13:53:25Z
dc.date.issued2024-04-19
dc.identifier.urihttps://repositorio.unicolmayor.edu.co/handle/unicolmayor/7057
dc.description.abstractLa esclerosis sistémica (ES) es una enfermedad autoinmune del tejido conectivo caracterizada por la presencia de vasculopatía, alteración de la respuesta inmune generando fibrosis en piel y órganos internos. Debido a su alta tasa de mortalidad y la complejidad en el tratamiento, se hace necesario intensificar la búsqueda de nuevos biomarcadores que permitan detectar la fase temprana de la enfermedad, facilitando así el diagnóstico temprano y el tratamiento oportuno. En la búsqueda de nuevos biomarcadores se ha propuesto a las quimioquinas como biomarcadores en las enfermedades autoinmunes. Un ejemplo es la Fractalcina/CX3CL, la cual puede actuar como molécula de adhesión en el endotelio inflamado, promoviendo la retención de monocitos y células T cuando está anclada a la membrana. Además, en su forma soluble, induce la migración de monocitos, células asesinas naturales (NK) y células T. Por tal motivo, se ha propuesto la Fractalcina/ CX3CL1 como candidata a biomarcador en ES, debido a su papel es el proceso inflamatorio en las enfermedades autoinmunes (EA), especialmente en la ES. Este proyecto tiene como objetivo identificar y describir Fractalcina/ CX3CL1 como un posible biomarcador predictivo para el diagnóstico de la esclerosis sistémica.spa
dc.description.tableofcontentsTabla de contenido Información General 1 1. RESUMEN 2 2. INTRODUCCIÓN 3 3. PLANTEAMIENTO DEL PROBLEMA: 4 4. ANTECEDENTES 6 5. MARCO REFERENCIAL 8 6. CRITERIOS DIAGNÓSTICOS 10 7. TIPOS DE ESCLEROSIS 15 7.1 Esclerosis sistémica limitada15 7.2 Esclerosis sistémica difusa 15 8. MANIFESTACIONES VASCULARES 17 9. MANIFESTACIONES CUTÁNEAS 18 10. FISIOPATOLOGÍA 21 11. FACTORES PREDISPONENTES DE LA ENFERMEDAD 23 12. VASCULOPATÍA25 13. RESPUESTA Y ACTIVACIÓN DEL SISTEMA INMUNE 26 14. PROCESO FIBRÓTICO29 15. TRATAMIENTO 31 16. BIOMARCADORES 32 16.1 Tipos de biomarcadores: 32 16.2 Quimiocinas 33 17. ESTRUCTURA BIOLÓGICA 37 18. EXPRESIÓN CELULAR 39 18.1 Células implicadas en la expresión de CX3CL1 en Enfermedades Autoinmunes (EAI). 39 19. UNIVERSO, POBLACIÓN Y MUESTRA 42 19.1 Tipo de estudio: 42 20. HIPÓTESIS, VARIABLES E INDICADORES 45 21. TÉCNICAS Y PROCEDIMIENTOS 49 22. RESULTADOS 52 23. DISCUSIÓN 72 24. CONCLUSIONES78 Bibliografía 80spa
dc.format.extent98p.spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherUniversidad Colegio Mayor de Cundinamarcaspa
dc.rightsDerechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/spa
dc.titleFractalcina/CX3CL1 y su rol en la fisiopatología en esclerosis sistémicaspa
dc.typeTrabajo de grado - Pregradospa
dc.contributor.corporatenameUniversidad Colegio Mayor de Cundinamarcaspa
dc.description.degreelevelPregradospa
dc.description.degreenameBacteriólogo(a) y Laboratorista Clínicospa
dc.publisher.facultyFacultad de Ciencias de la Saludspa
dc.publisher.placeBogotá D.Cspa
dc.publisher.programBacteriología y Laboratorio Clínicospa
dc.relation.referencesLepri G, Bellando Randone S, Matucci Cerinic M, Guiducci S. Early diagnosis of systemic sclerosis, where do we stand today? Expert Rev Clin Immunol. 2022 Jan 2;18(1):1–3.spa
dc.relation.referencesMasi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980 May;23(5):581–90.spa
dc.relation.referencesVan den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013 Nov 3;65(11):2737–47.spa
dc.relation.referencesFabri M, Hunzelmann N. Differential diagnosis of scleroderma and pseudoscleroderma. JDDG. 2007 Nov;5(11):977–83.spa
dc.relation.referencesBurbelo PD, Gordon SM, Waldman M, Edison JD, Little DJ, Stitt RS, et al. Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLoS One. 2019 Mar 26;14(3):e0214202.spa
dc.relation.referencesDenton CP, Khanna D. Systemic sclerosis. The Lancet. 2017 Oct;390(10103):1685–99.spa
dc.relation.referencesSobolewski P, Maślińska M, Wieczorek M, Łagun Z, Malewska A, Roszkiewicz M, et al. Systemic sclerosis – multidisciplinary disease: clinical features and treatment. Rheumatology. 2019 Sep 24;57(4):221–33.spa
dc.relation.referencesLepri G, Bellando Randone S, Matucci Cerinic M, Guiducci S. Early diagnosis of systemic sclerosis, where do we stand today? Expert Rev Clin Immunol. 2022 Jan 2;18(1):1–3.spa
dc.relation.referencesCutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol. 2019 Jul 3;15(7):753–64.spa
dc.relation.referencesvan den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov 3;72(11):1747–55.spa
dc.relation.referencesWik L, Nordberg N, Broberg J, Björkesten J, Assarsson E, Henriksson S, et al. Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide Analysis. Molecular & Cellular Proteomics. 2021;20:100168spa
dc.relation.referencesAspe Unanue L, González Hermosa MR, Gardeazabal García J. Esclerodermia (esclerosis sistémica). Piel. 2010 May;25(5):252–66.spa
dc.relation.referencesFernández-Ávila DG, Bernal-Macías S, Gutiérrez JM, Rincón DN, Rosselli D. Prevalence of systemic sclerosis in Colombia: Data from the National Health Registry 2012–2016. J Scleroderma Relat Disord. 2020 Jun 19;5(2):137–42.spa
dc.relation.referencesRodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 1979 Feb;22(2):130–40.spa
dc.relation.referencesESCLEROSIS SISTÉMICA (ESCLERODERMIA). Consejo General De Colegios Oficiales De Farmaceuticos [Internet]. :5–19. Available from: https://www.cofbadajoz.com/wp-content/uploads/2018/03/ESCLEROSIS-SISTÉMICA.pdfspa
dc.relation.referencesThombs BD, Hudson M, Taillefer SS, Baron M. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthritis Rheum. 2008 Apr 15;59(4):504–9.spa
dc.relation.referencesFabri M, Hunzelmann N. Differential diagnosis of scleroderma and pseudoscleroderma. JDDG. 2007 Nov;5(11):977–83.spa
dc.relation.referencesColmenares Roldán LM, Velásquez Franco CJ, Mesa Navas MA. Capillaroscopy in systemic sclerosis: A narrative literature review. Revista Colombiana de Reumatología (English Edition). 2016 Oct;23(4):250–8.spa
dc.relation.referencesHASSAN ML. CONSENSO SOBRE ESCLERODERMIA ACTUALIZACIÓN 2015. 2015.spa
dc.relation.referencesRodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 1979 Feb;22(2):130–40.spa
dc.relation.referencesESCLEROSIS SISTÉMICA (ESCLERODERMIA). Consejo General De Colegios Oficiales De Farmaceuticos. :5–19.spa
dc.relation.referencesAspe Unanue L, González Hermosa MR, Gardeazabal García J. Esclerodermia (esclerosis sistémica). Piel. 2010 May;25(5):252–66.spa
dc.relation.referencesAspe Unanue L, González Hermosa MR, Gardeazabal García J. Esclerodermia (esclerosis sistémica). Piel. 2010 May;25(5):252–66.spa
dc.relation.referencesAllanore Y. Esclerodermia sistémica: epidemiología, fisiopatología y clínica. EMC - Aparato Locomotor. 2022 Dec;55(4):1–27.spa
dc.relation.referencesAllanore Y. Esclerodermia sistémica: epidemiología, fisiopatología y clínica. EMC - Aparato Locomotor. 2022 Dec;55(4):1–27.spa
dc.relation.referencesDenton CP, Khanna D. Systemic sclerosis. The Lancet. 2017 Oct;390(10103):1685–99.spa
dc.relation.referencesGreiffo FR, Viteri-Alvarez V, Frankenberger M, Dietel D, Ortega-Gomez A, Lee JS, et al. CX3CR1–fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. European Respiratory Journal. 2020 Feb;55(2):1900460spa
dc.relation.referencesThoreau B, Chaigne B, Renaud A, Mouthon L. Pathophysiology of systemic sclerosis. Presse Med. 2021 Apr;50(1):104087.spa
dc.relation.referencesHattori M, Yokoyama Y, Hattori T, Motegi S, Amano H, Hatada I, et al. Global <scp>DNA</scp> hypomethylation and hypoxia‐induced expression of the ten eleven translocation ( <scp>TET</scp> ) family, <scp>TET</scp> 1, in scleroderma fibroblasts. Exp Dermatol. 2015 Nov 14;24(11):841–6.spa
dc.relation.referencesJoven BE, Carreira PE. Síndrome de Raynaud: etiología y manejo. Reumatol Clin. 2008 Mar;4(2):59–66.spa
dc.relation.referencesBhattacharyya S, Varga J. Emerging Roles of Innate Immune Signaling and Toll-Like Receptors in Fibrosis and Systemic Sclerosis. Curr Rheumatol Rep. 2015 Jan 22;17(1):2.spa
dc.relation.referencesSociedad Cubana de Reumatologíía SE, Grupo Nacional de Reumatologíía (Cuba) G, Avilés del Campo E, Pérez Torres L. Revista cubana de reumatologíía. Vol. 16, Revista Cubana de Reumatología. Sociedad Cubana de Reumatología; 2014. 304–308 p.spa
dc.relation.referencesYoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018 Mar;195:76–82.spa
dc.relation.referencesSonsoles Piera-Velázquez CTDerk y SAJ. PATOGÉNESIS DE LA ESCLEROSIS SISTÉMICA. SISBIB. 2004;Revista Peruana de Reumatología.spa
dc.relation.referencesJiménez-Romero ME, Caro-Gómez I. Biomarcadores en el cáncer de próstata. Implicación en la práctica clínica. Rev Mex Urol. 2014 Jul;74(4):226–33.spa
dc.relation.referencesGiacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Berardicurti O, Bombardieri M, et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmun Rev. 2019 Jan;18(1):93–106.spa
dc.relation.referencesGoodnow CC, Sprent J, de St Groth BF, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature. 2005 Jun 2;435(7042):590–7.spa
dc.relation.referencesHarrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology. 2022 Dec 8;76(6):1862–79.spa
dc.relation.referencesLee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009 Mar;8(5):379–83.spa
dc.relation.referencesAntonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, et al. CXCL10 ( ) and CCL2 ( ) chemokines in systemic sclerosis a longitudinal study. Rheumatology. 2008 Jan 1;47(1):45–9.spa
dc.relation.referencesZheng B, Keen KJ, Fritzler MJ, Ryerson CJ, Wilcox P, Whalen BA, et al. Circulating cytokine levels in systemic sclerosis related interstitial lung disease and idiopathic pulmonary fibrosis. Sci Rep. 2023 Apr 24;13(1):6647.spa
dc.relation.referencesLande R, Lee EY, Palazzo R, Marinari B, Pietraforte I, Santos GS, et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis. Nat Commun. 2019 May 1;10(1):1731.spa
dc.relation.referencesSilva-Cardoso SC, Tao W, Angiolilli C, Lopes AP, Bekker CPJ, Devaprasad A, et al. CXCL4 Links Inflammation and Fibrosis by Reprogramming Monocyte-Derived Dendritic Cells in vitro. Front Immunol. 2020 Sep 17;11.spa
dc.relation.referencesAffandi AJ, Carvalheiro T, Ottria A, de Haan JJ, Brans MAD, Brandt MM, et al. CXCL4 drives fibrosis by promoting several key cellular and molecular processes. Cell Rep. 2022 Jan;38(1):110189.spa
dc.relation.referencesMendez-Enriquez E, García-Zepeda EA. The multiple faces of CCL13 in immunity and inflammation. Inflammopharmacology. 2013 Dec 12;21(6):397–406.spa
dc.relation.referencesYanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, et al. CCL13 is a promising diagnostic marker for systemic sclerosis. British Journal of Dermatology. 2010 Feb;162(2):332–6.spa
dc.relation.referencesGambichler T, Yilmaz E, Höxtermann S, Kolios A, Moritz R, Bechara FG, et al. Serum CCL13 levels in patients with systemic sclerosis and controls. British Journal of Dermatology. 2011 Jul;165(1):216–8.spa
dc.relation.referencesLi L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.spa
dc.relation.referencesMecca C, Giambanco I, Donato R, Arcuri C. Microglia and Aging: The Role of the TREM2–DAP12 and CX3CL1-CX3CR1 Axes. Int J Mol Sci. 2018 Jan 22;19(1):318.spa
dc.relation.referencesArai M, Ikawa Y, Chujo S, Hamaguchi Y, Ishida W, Shirasaki F, et al. Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. J Dermatol Sci. 2013 Mar;69(3):250–8.spa
dc.relation.referencesBazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997 Feb;385(6617):640–4.spa
dc.relation.referencesHarrison JK, Fong AlanM, Swain PeterAW, Chen S, Yu YReiA, Salafranca MN, et al. Mutational Analysis of the Fractalkine Chemokine Domain. Journal of Biological Chemistry. 2001 Jun;276(24):21632–41.spa
dc.relation.referencesChandrasekar B, Melby PC, Sarau HM, Raveendran M, Perla RP, Marelli-Berg FM, et al. Chemokine-Cytokine Cross-talk. Journal of Biological Chemistry. 2003 Feb;278(7):4675–86.spa
dc.relation.referencesMattison HA, Nie H, Gao H, Zhou H, Hong JS, Zhang J. Suppressed pro-inflammatory response of microglia in CX3CR1 knockout mice. J Neuroimmunol. 2013 Apr;257(1–2):110–5.spa
dc.relation.referencesHaskell CA, Cleary MD, Charo IF. Unique Role of the Chemokine Domain of Fractalkine in Cell Capture. Journal of Biological Chemistry. 2000 Nov;275(44):34183–9.spa
dc.relation.referencesPawelec P, Ziemka-Nalecz M, Sypecka J, Zalewska T. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders. Cells. 2020 Oct 13;9(10):2277.spa
dc.relation.referencesHoffmann-Vold AM, Weigt SS, Palchevskiy V, Volkmann E, Saggar R, Li N, et al. Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. PLoS One. 2018 Nov 20;13(11):e0206545.spa
dc.relation.referencesMarchesi F, Locatelli M, Solinas G, Erreni M, Allavena P, Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol. 2010 Jul;224(1–2):39–44.spa
dc.relation.referencesMoon SO, Kim W, Sung MJ, Lee S, Kang KP, Kim DH, et al. Resveratrol Suppresses Tumor Necrosis Factor-α-Induced Fractalkine Expression in Endothelial Cells. Mol Pharmacol. 2006 Jul;70(1):112–9.spa
dc.relation.referencesDénes Á, Ferenczi S, Halász J, Környei Z, Kovács KJ. Role of CX3CR1 (Fractalkine Receptor) in Brain Damage and Inflammation Induced by Focal Cerebral Ischemia in Mouse. Journal of Cerebral Blood Flow & Metabolism. 2008 Oct 25;28(10):1707–21.spa
dc.relation.referencesRosendahl A, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022 Mar 2;38(3):187–95.spa
dc.relation.referencesJones BA, Beamer M, Ahmed S. Fractalkine/CX3CL1: A Potential New Target for Inflammatory Diseases. Mol Interv. 2010 Oct 1;10(5):263–70.spa
dc.relation.referencesJulia V, Staumont-Salle D, Dombrowicz D. Rôle de la fractalkine/CX3CL1 et de son récepteur CX3CR1 dans les pathologies allergiques. médecine/sciences. 2016 Mar 23;32(3):260–6.spa
dc.relation.referencesMionnet C, Buatois V, Kanda A, Milcent V, Fleury S, Lair D, et al. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med. 2010 Nov;16(11):1305–12spa
dc.relation.referencesS Sato, T-Echigo, Y Hamaguchi, M Yasui, K Takehara. Expresión regulada por aumento de fractalquina/CX 3 CL1 y CX 3 CR1 en pacientes con esclerosis sistémica. BMJ Journals. 2004 Dec 4;spa
dc.relation.referencesMarasini B, Cossutta R, Selmi C, Pozzi MR, Gardinali M, Massarotti M, et al. Polymorphism of the Fractalkine Receptor CX3CR1 and Systemic Sclerosis-associated Pulmonary Arterial Hypertension. Clin Dev Immunol. 2005;12(4):275–9.spa
dc.relation.referencesBalabanian K, Foussat A, Dorfmüller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, et al. CX 3 C Chemokine Fractalkine in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2002 May 15;165(10):1419–25.spa
dc.relation.referencesGuo L, Lu X, Wang Y, Bao C, Chen S. Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus. Exp Ther Med. 2017 Oct;14(4):3153–8.spa
dc.relation.referencesQuantikineTM ELISA. Human CX3CL1/Fractalkine Quantikine ELISA Kit. 2021 May.spa
dc.relation.referencesLuong VH, Utsunomiya A, Chino T, Doanh LH, Matsushita T, Obara T, et al. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the <scp>CX</scp> 3 <scp>CL</scp> 1/ <scp>CX</scp> 3 <scp>CR</scp> 1 Pathway in Experimental Mouse Models of Systemic Sclerosis. Arthritis & Rheumatology. 2019 Nov 11;71(11):1923–34.spa
dc.relation.referencesNanki T, Imai T, Kawai S. Fractalkine/CX3CL1 in rheumatoid arthritis. Mod Rheumatol. 2017 May 4;27(3):392–7.spa
dc.relation.referencesLu X. Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer. Curr Med Chem. 2022 Dec;29(41):6228–46.spa
dc.relation.referencesGreiffo FR, Viteri-Alvarez V, Frankenberger M, Dietel D, Ortega-Gomez A, Lee JS, et al. CX3CR1–fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. European Respiratory Journal. 2020 Feb;55(2):1900460.spa
dc.relation.referencesJones B, Koch AE, Ahmed S. Pathological Role of Fractalkine/CX3CL1 in Rheumatic Diseases: A Unique Chemokine with Multiple Functions. Front Immunol. 2012;2.spa
dc.relation.referencesHasegawa M. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis. 2005 Jan 1;64(1):21–8.spa
dc.relation.referencesJones B, Koch AE, Ahmed S. Pathological Role of Fractalkine/CX3CL1 in Rheumatic Diseases: A Unique Chemokine with Multiple Functions. Front Immunol. 2012;2.spa
dc.relation.referencesJones B, Koch AE, Ahmed S. Pathological Role of Fractalkine/CX3CL1 in Rheumatic Diseases: A Unique Chemokine with Multiple Functions. Front Immunol. 2012;2.spa
dc.relation.referencesGuo L, Lu X, Wang Y, Bao C, Chen S. Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus. Exp Ther Med. 2017 Oct;14(4):3153–8.spa
dc.relation.referencesS Sato, T-Echigo, Y Hamaguchi, M Yasui, K Takehara. Expresión regulada por aumento de fractalquina/CX 3 CL1 y CX 3 CR1 en pacientes con esclerosis sistémica. BMJ Journals. 2004 Dec 4;spa
dc.relation.referencesHoffmann-Vold AM, Weigt SS, Palchevskiy V, Volkmann E, Saggar R, Li N, et al. Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. PLoS One. 2018 Nov 20;13(11):e0206545.spa
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccessspa
dc.rights.creativecommonsAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)spa
dc.subject.proposalEsclerosis sistémicaspa
dc.subject.proposalAutoinmunidadspa
dc.subject.proposalVasculopatíaspa
dc.subject.proposalRespuesta inmunespa
dc.subject.proposalBiomarcadoresspa
dc.subject.proposalQuimiocinaspa
dc.subject.proposalEndoteliospa
dc.subject.proposalDiagnósticospa
dc.subject.proposalTratamientospa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.redcolhttps://purl.org/redcol/resource_type/TPspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.rights.coarhttp://purl.org/coar/access_right/c_14cbspa


Ficheros en el ítem

Thumbnail
Nombre:
ENTREGA DOCUMENTO FINAL TESIS.pdf
Tamaño:
1.074Mb
Formato:
PDF
Ver/
Thumbnail
Nombre:
CARTA DERECHOS DE AUTOR IP ...
Tamaño:
102.0Kb
Formato:
PDF
Ver/
Thumbnail
Nombre:
FORMATO IDENTIFICACIÓN TRABAJOS ...
Tamaño:
282.4Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024
Excepto si se señala otra cosa, la licencia del ítem se describe como Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024